Cell Biosciences Inc. acquired Protein Forest Inc. for an undisclosed amount, adding the Lexington, Mass.-based sample preparation technology firm’s ProteomeChip product line to its roster of protein analysis technologies.
Protein Forest‘s digital product line is used to fractionate proteins from complex biological samples used in proteomics research. Santa Clara, Calif.-based Cell Biosciences said ProteomeChip can be used at the front end of sample preparation with a variety of techniques, including its own nanoproteomic platforms.
The company didn’t say how much the deal was worth, but it raised $4 million “in connection with the all-stock acquisition” in a funding round led by Novo A/S, the holding company for Danish diabetes giant Novo Nordisk.
Ric Schumacher, CEO of the Easton, Mass.-based pressure cycling technology maker, told MassDevice that it’s unclear what the impact of the Cell Biosciences buyout will be on his arrangement with Protein Forest, but that it might wind up being an even better deal in the end.
“I’m expecting that the agreement will continue in some respect. It might even broaden the advantages of this,” Schumacher said. “Cell Biosciences is a much larger company than Protein Forest, so it’s possible that the agreement might even be enhanced.”